➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
AstraZeneca
Harvard Business School
Dow
Medtronic

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Patent: 8,394,076

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,394,076
Title:Laser assisted therapeutic agent delivery into a targeted tissue
Abstract: The present invention involves selectively breaking down or altering a blocking tissue by irradiating the blocking tissue with a laser irradiation. Breaking down the blocking tissue allows the delivery of therapeutic agents through the blocking tissue to a target tissue. An area of the blocking tissue is selected for treatment. The selected area is irradiated with a laser to induce an alteration or breakdown of the blocking tissue. Areas not irradiated are not affected. Once the selected area of the blocking tissue is treated, a therapeutic agent can be delivered to the selected area and passed through the altered or broken down blocking tissue to the target tissue. The blocking tissue will then undergo a healing response after a period of time. The present invention may be used to treat the retina or subretinal space of a patient\'s eye through the blocking tissue of the Retinal Pigment Epithelium (RPE).
Inventor(s): Latina; Mark A. (North Andover, MA)
Assignee:
Application Number:12/436,511
Patent Claims:see list of patent claims

Details for Patent 8,394,076

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial 2028-05-14 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial 2028-05-14 RX Orphan search
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30   Start Trial 2028-05-14 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Boehringer Ingelheim
McKinsey
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.